Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BMS-911543

Known as: JAK2 Inhibitor BMS-911543 
An orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. JAK2 inhibitor BMS… Expand
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.
JAK2 kinase inhibitors are a promising new class of agents for the treatment of myeloproliferative neoplasms and have potential… Expand
2015
2015
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Activation of Janus kinase 2 (JAK2), frequently as a result of the JAK2(V617F) mutation, is a characteristic feature of the… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2015
2015
Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer
The Jak/STAT pathway is activated in human pancreatic ductal adenocarcinoma (PDAC) and cooperates with mutant Kras to drive… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2015
2015
Ni-Catalyzed C-H Functionalization in the Formation of a Complex Heterocycle: Synthesis of the Potent JAK2 Inhibitor BMS-911543.
BMS-911543 is a complex pyrrolopyridine investigated as a potential treatment for myeloproliferative disorders. The development… Expand
2015
2015
A UHPLC-MS/MS bioanalytical assay for the determination of BMS-911543, a JAK2 inhibitor, in human plasma.
  • Jane Liu, L. Yuan, +4 authors Q. Ji
  • Journal of chromatography. B, Analytical…
  • 2015
    • Corpus ID: 5390613
Herein we report a rapid, accurate and robust UHPLC-MS/MS assay for the quantitation of BMS-911453, a Janus kinase 2 inhibitor… Expand
  • figure 3
  • figure 2
  • figure 4
  • figure 5
  • table 1
2014
2014
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells
Imatinib Mesylate (IM) and other tyrosine kinase inhibitor (TKI) therapies have had a major impact on the treatment of chronic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis
Background BMS-911543 is an oral, selective small-molecule inhibitor of JAK2 (IC50=1.1nM) with potent anti-proliferative and… Expand
Highly Cited
2012
Highly Cited
2012
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2
We report the characterization of BMS-911543, a potent and selective small-molecule inhibitor of the Janus kinase (JAK) family… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2012
Review
2012
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
JAK-STAT (Janus associated kinase-signal transducer and activator of transcription) pathway plays a critical role in transduction… Expand
  • figure 1
  • table 1
  • table 2
2010
2010
Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2
Abstract 4112 We report the characterization of BMS-911543, a potent and functionally selective small molecule inhibitor of the… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE